ACM
HRTX icon

Atika Capital Management’s Heron Therapeutics HRTX Stock Holding History

Atika Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-60,000
Closed -$831K – 85
2017
Q2 		$831K Buy
+60,000
New +$869K 0.29% 71

Other funds holding HRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Atika Capital Management's HRTX Position: Q1 2018 in Review

Atika Capital Management sold out of Heron Therapeutics (HRTX) in Q1 2018, closing a stake of 90,000 shares — an estimated $1.63M sold.

Atika Capital Management first reported a position in HRTX in Q1 2017 and held it in 4 quarters. The position peaked at $1.63M in Q4 2017. 152 funds tracked by Wall St. Rank hold HRTX as of Q1 2018.

  • Atika Capital Management reported no remaining Heron Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Atika Capital Management sold 90,000 Heron Therapeutics shares in Q1 2018, an estimated $1.63M.
  • Atika Capital Management first reported a position in Heron Therapeutics in Q1 2017 and held it in 4 quarters.
  • Atika Capital Management's Heron Therapeutics position peaked at $1.63M in Q4 2017.
  • 152 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2018.

Based on Atika Capital Management's 13F filing for Q1 2018, filed 15 May 2018.